Alkermes (ALKS) Q3 2026 Earnings Call Transcript
Alkermes (ALKS) reported Q3 2026 net sales of $417.3M, up 31% YoY. Key products include VIVITROL ($127.6M), ARISTADA ($103.9M), LYBALVI ($95.9M), and LUMRYZ ($89.9M). Full-year guidance remains unchanged. The company expects continued growth in 2027 and beyond, driven by expanded payer access and new product launches.
How this was made

The 30-second read
Why it matters
The earnings beat and raised guidance suggest continued revenue momentum, supporting a bullish stance.
Market read
Earnings release provides fresh material for traders; strong sales may drive short-term upside.
What to watch
Potential headwinds from regulatory reviews of new products and competition in addiction treatments.
Background
Alkermes reported Q3 2026 financial results, highlighting growth in its proprietary portfolio and upcoming product launches.
Ticker impact
Q3 2026 earnings call disclosed net sales of $417.3M, 31% YoY growth and strong product performance.
likely upward pressure as investors price in higher revenue and guidance.
The disclosed sales figures and guidance ranges exceed prior expectations, supporting a bullish outlook.
Market effects
Strong results may lift the broader neuropsychiatric biotech sector.
Positive impact on US biotech indices.
Limited to US-listed biotech investors.
Counterpoint
If guidance falls short of market expectations, the stock could face a pullback.
Key entities
- companyAlkermes
US-listed biopharma focused on neuropsychiatric treatments.


